Carlsmed (CARL) Common Equity (2024 - 2026)

Carlsmed's Common Equity history runs 3 years deep, the most recent figure standing at $92.2 million for Q1 2026.

• Quarterly Common Equity rose 220.41% year-over-year to $92.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.2 million (up 220.41% YoY) and the FY2025 annual result came in at $98.9 million, up 239.98% from the prior year.
• Common Equity was $92.2 million for Q1 2026 at Carlsmed, down from $98.9 million in the prior quarter.
• Across five years, Common Equity topped out at $106.7 million in Q3 2025 and bottomed at -$83.1 million in Q2 2025.
• A 3-year average of -$7.0 million and a median of -$61.9 million in 2024 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 261.54% in 2025, while the deepest fall reached 43.88% in 2025.
• Carlsmed's Common Equity stood at -$70.6 million in 2024, then jumped by 239.98% to $98.9 million in 2025, then slipped by 6.7% to $92.2 million in 2026.
• Business Quant data shows CARL's Common Equity at $92.2 million in Q1 2026, $98.9 million in Q4 2025, and $106.7 million in Q3 2025.